Search research articles
Contact Us
Filters
Showing results (1-10 of 51) with videos related to
Page
of 6
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 20, 2024
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
Shuo Kang, Jintuo Yin
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 26, 2025
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China
Shan Zhao, Shuo Kang
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
|
November 3, 2022
[Research Progress in Mechanism of Lipid Nephrotoxicity]
Shuo Kang, Xuan Zhang
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 4, 2023
Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis
Mochong Liao, Shuo Kang
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 8, 2023
Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
Shuo Kang, Huanlong Liu
Scientific Reports
|
December 10, 2025
Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer
Shan Zhao, Shuo Kang
Scientific Reports
|
October 21, 2025
Cost effectiveness and pricing strategy of first line benmelstobart combination treatment for extensive stage small cell lung cancer in China
Shan Zhao, Shuo Kang
Expert Review of Pharmacoeconomics & Outcomes Research
|
February 25, 2021
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
Guoqiang Liu, Shuo Kang
Expert Review of Pharmacoeconomics & Outcomes Research
|
January 19, 2023
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China
Fangjian Shang, Boyuan Zhang, Shuo Kang
Medicine
|
December 30, 2025
Low-grade oncocytic tumor of kidney: A case report
Ting-Shuo Kang, Yi-Zhong Chen
Page
of 6
Search research articles
Search
Showing results (1-10 of 51) with videos related to
Sort By:
Page
of 6
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 20, 2024
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis
Shuo Kang, Jintuo Yin
Expert Review of Pharmacoeconomics & Outcomes Research
|
March 26, 2025
Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China
Shan Zhao, Shuo Kang
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
|
November 3, 2022
[Research Progress in Mechanism of Lipid Nephrotoxicity]
Shuo Kang, Xuan Zhang
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 4, 2023
Economic evaluation of sintilimab versus docetaxel as second-line treatment for patients with advanced or metastatic squamous non-small-cell lung cancer in China: a model-based cost-effectiveness analysis
Mochong Liao, Shuo Kang
Expert Review of Pharmacoeconomics & Outcomes Research
|
November 8, 2023
Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
Shuo Kang, Huanlong Liu
Scientific Reports
|
December 10, 2025
Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer
Shan Zhao, Shuo Kang
Scientific Reports
|
October 21, 2025
Cost effectiveness and pricing strategy of first line benmelstobart combination treatment for extensive stage small cell lung cancer in China
Shan Zhao, Shuo Kang
Expert Review of Pharmacoeconomics & Outcomes Research
|
February 25, 2021
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
Guoqiang Liu, Shuo Kang
Expert Review of Pharmacoeconomics & Outcomes Research
|
January 19, 2023
Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China
Fangjian Shang, Boyuan Zhang, Shuo Kang
Medicine
|
December 30, 2025
Low-grade oncocytic tumor of kidney: A case report
Ting-Shuo Kang, Yi-Zhong Chen
Page
of 6